Combined Epigenetic and Immunotherapy for Mantle Cell Lymphoma



August 23, 2022

Oncotarget published this research paper on August 16, 2022 in Volume 13, entitled, "Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma" by researchers from Department of Medicine, Pennsylvania State University College of Medicine and Penn State Hershey Cancer Institute, Hershey, PA; Department of Hematology/Oncology, Penn State Hershey Cancer Institute, Hershey, PA; BayCare Medical Group, Cassidy Cancer Center, Winter Haven, FL; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY; Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD; Department of Pharmacology, University of Virginia, Charlottesville, VA; Department of Public Health Sciences, The Pennsylvania State University College of Medicine, Hershey, PA; Department of Medicine/Hematology-Oncology, UVA Cancer Center, Charlottesville, VA; Department of Anatomic Pathology, Pennsylvania State University College of Medicine, Hershey, PA; Department of Medicine and Cancer Center, University of Arizona College of Medicine, Tucson, AZ; Department of Medicine, Oregon Health and Science University, Portland, OR; Beverly Hills Cancer Center, Beverly Hills, CA. DOI - Correspondence to - Francis R. LeBlanc - Abstract Classical MCL (cMCL) constitutes 6–8% of all B cell NHL. Despite recent advances, MCL is incurable except with allogeneic stem cell transplant. Blastic mantle cell lymphoma (bMCL) is a rarer subtype of cMCL associated with an aggressive clinical course and poor treatment response, frequent relapse and poor outcomes. We treated 13 bMCL patients with combined epigenetic and immunotherapy treatment consisting of vorinostat, cladribine and rituximab (SCR). We report an increased OS greater than 40 months with several patients maintaining durable remissions without relapse for longer than 5 years. This is remarkably better then current treatment regimens which in bMCL range from 14.5-24 months with conventional chemotherapy regimens. We demonstrate that the G/A870 CCND1 polymorphism is predictive of blastic disease, nuclear localization of cyclinD1 and response to SCR therapy. The major resistance mechanisms to SCR therapy are loss of CD20 expression and evasion of treatment by sanctuary in the CNS. These data indicate that administration of epigenetic agents improves efficacy of anti-CD20 immunotherapies. This approach is promising in the treatment of MCL and potentially other previously treated refractory cancers. Sign up for free Altmetric alerts about this article - Keywords - epigenetics, blastic mantle cell lymphoma, cladribine About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. To learn more about Oncotarget, please visit and connect with us: SoundCloud - Facebook - Twitter - Instagram - YouTube - LinkedIn - Pinterest - Reddit - Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

BioprocessingCancer ResearchDrug DiscoveryImmunology

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.